J
Josep M. Campistol
Researcher at University of Barcelona
Publications - 316
Citations - 23044
Josep M. Campistol is an academic researcher from University of Barcelona. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 69, co-authored 305 publications receiving 19623 citations. Previous affiliations of Josep M. Campistol include Carlos III Health Institute & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Keiichiro Suzuki,Yuji Tsunekawa,Reyna Hernández-Benítez,Reyna Hernández-Benítez,Jun Wu,Jun Wu,Jie Zhu,Jie Zhu,Euiseok J. Kim,Fumiyuki Hatanaka,Mako Yamamoto,Toshikazu Araoka,Toshikazu Araoka,Zhe Li,Masakazu Kurita,Tomoaki Hishida,Mo Li,Emi Aizawa,Shicheng Guo,Song Chen,April Goebl,Rupa Devi Soligalla,Jing Qu,Tingshuai Jiang,Xin Fu,Xin Fu,Maryam Jafari,Concepcion Rodriguez Esteban,W. Travis Berggren,Jeronimo Lajara,Estrella Núñez-Delicado,Pedro Guillen,Josep M. Campistol,Fumio Matsuzaki,Guang-Hui Liu,Pierre J. Magistretti,Kun Zhang,Edward M. Callaway,Kang Zhang,Juan Carlos Izpisua Belmonte +39 more
TL;DR: The HITI method presented here establishes new avenues for basic research and targeted gene therapies and demonstrates the efficacy of HITI in improving visual function using a rat model of the retinal degeneration condition retinitis pigmentosa.
Journal ArticleDOI
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Carl G. Groth,Lars Bäckman,José-Maria Morales,Roy Y. Calne,Henri Kreis,Philippe Lang,Jean-Louis Touraine,Kerstin Claesson,Josep M. Campistol,Dominique Durand,L. Wramner,Christina Brattström,Bernard Charpentier +12 more
TL;DR: Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus as discussed by the authors.
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Pierre Lozeron,Ole B. Suhr,Josep M. Campistol,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason Chan,Jeff Packman,Amy Wilson,Donna R. Grogan +16 more
TL;DR: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment.